A promoter variant in the OTC gene associated with late and variable age of onset hyperammonemia

Sangwoo T. Han, Katherine J. Anderson, Hans Tómas Björnsson*, Nicola Longo, David Valle

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Ornithine transcarbamylase deficiency (OTCD) is an X-linked inborn error caused by loss of function variants in the OTC gene typically associated with severe neonatal hyperammonemia. Rare examples of late-onset OTCD have also been described. Here, we describe an OTC promoter variant, c.-106C>A, in a conserved HNF4a binding site, identified in two male siblings in Family 1 whose first and only recognized episodes of severe hyperammonemia occurred at ages 14 and 39 years, respectively. We identified the same OTC variant segregating in a large family with late-onset OTCD with variable expressivity (Family 2). We show that this OTC promoter variant reduces expression >5-fold in a dual-luciferase assay that tests promoter function. Addition of an upstream OTC enhancer increases expression of both the wild type and the c.-106C>A variant promoter constructs >5-fold with the mutant promoter still about fourfold lower than the wild type. Thus, in both contexts, the promoter variant results in substantially lower OTC expression. Under normal demand on urea cycle function, OTC expression in hemizygous males, although reduced, is sufficient to meet the demand for waste nitrogen excretion. However, in response to severe metabolic stress with attendant increased requirements on urea cycle function, the impaired promoter function results in inadequate OTC expression with resultant hyperammonemia. In the absence of precipitating events, hemizygotes with this allele are asymptomatic, explaining the late age of onset of hyperammonemia in affected individuals and the incomplete penetrance observed in some individuals in Family 2.

Original languageEnglish
Pages (from-to)710-718
Number of pages9
JournalJournal of Inherited Metabolic Disease
Volume45
Issue number4
DOIs
Publication statusPublished - 28 Jun 2022

Bibliographical note

Funding Information:
Icelandic Research Fund, Grant/Award Numbers: 195835, 206806, 217988; Icelandic Technology Development Fund, Grant/Award Number: 2010588‐0611; National Heart, Lung, and Blood Institute and National Human Genome Research Institute, Grant/Award Number: UM1HG006542 Funding information

Funding Information:
D.V. is supported by the National Heart Lung and Blood Institute and the National Human Genome Research Institute (UM1HG006542). H.T.B. is supported by grants from the Icelandic Research Fund (#195835, #206806, and #217988) and the Icelandic Technology Development Fund (#2010588‐0611). H.T.B. is a consultant for Mahzi therapeutics.

Publisher Copyright:
© 2022 SSIEM.

Other keywords

  • late onset
  • noncoding DNA
  • OTC deficiency
  • promoter variant
  • regulatory DNA sequence
  • Humans
  • Male
  • Urea/metabolism
  • Young Adult
  • Ornithine Carbamoyltransferase/genetics
  • Adolescent
  • Age of Onset
  • Alleles
  • Adult
  • Hyperammonemia/etiology
  • Ornithine Carbamoyltransferase Deficiency Disease/complications

Fingerprint

Dive into the research topics of 'A promoter variant in the OTC gene associated with late and variable age of onset hyperammonemia'. Together they form a unique fingerprint.

Cite this